NASCET CriteriaCarotid Artery Stenosis Duplex Velocity Grading
Hemodynamic Velocity
cm/s
Measured in the internal carotid artery (ICA) via duplex ultrasound.
Stenosis Grading
Provide Peak Systolic Velocity (PSV) measurements to estimate internal carotid artery stenosis severity.
Guidelines & Evidence
Verified
Last Review: 2026
When to Use
What is Carotid Stenosis (NASCET Method)?
Carotid stenosis refers to the narrowing of the internal carotid artery (ICA), typically due to atherosclerosis, most commonly at the carotid bifurcation. The NASCET (North American Symptomatic Carotid Endarterectomy Trial) method is the standard angiographic measurement technique for quantifying stenosis severity. It calculates the percentage of diameter reduction as: (1 - [minimal residual lumen diameter at the stenosis] / [normal distal ICA diameter beyond the stenosis]) Ă 100%. This measurement determines eligibility for carotid revascularization (carotid endarterectomy, CEA; or carotid artery stenting, CAS). Severe stenosis (70-99%) in symptomatic patients has a high 2-year stroke risk (up to 26% with medical therapy alone), which is significantly reduced by CEA (number needed to treat, NNT = 6). Moderate stenosis (50-69%) in symptomatic patients also benefits from CEA (NNT = 15), while mild stenosis (<50%) does not. In asymptomatic patients, CEA is beneficial for severe stenosis (60-99%) if perioperative risk is low (NNT = 20-30 over 5 years).
Primary Clinical Indications
Symptomatic carotid stenosis â Patients with recent (within 6 months) ipsilateral hemispheric or retinal transient ischemic attack (TIA) or minor ischemic stroke. Carotid revascularization (CEA or CAS) is indicated for 70-99% stenosis (Class I) and for 50-69% stenosis (Class I, but benefit less certain).
Asymptomatic carotid stenosis â Patients with no prior ipsilateral stroke or TIA but with significant stenosis on screening ultrasound. CEA is indicated for 60-99% stenosis if perioperative risk is low (<3%) and patient life expectancy >5 years (Class IIa).
Pre-operative assessment for cardiac surgery â Patients undergoing coronary artery bypass grafting (CABG) or valve surgery with carotid bruit or known stenosis; however, routine screening not recommended. Combined CEA + CABG may be considered for severe symptomatic or bilateral severe asymptomatic stenosis.
Evaluation of carotid bruit â Carotid bruit on physical exam has low sensitivity and specificity for significant stenosis; carotid duplex ultrasound is indicated to diagnose or exclude stenosis.
Monitoring progression of known stenosis â Serial carotid duplex ultrasound (every 6-12 months) to assess stenosis progression (increase of >20% or progression to severe range prompts consideration of revascularization).
Pre-procedural planning before CEA or CAS â Angiography (CTA or invasive) to confirm degree of stenosis, plaque morphology (ulceration, calcification, thrombus), and anatomy (tortuosity, arch type) for procedure planning.
Evaluation for recurrent stenosis after CEA or CAS â Follow-up duplex ultrasound at 1, 6, and 12 months, then annually to detect restenosis (>50% is significant; >80% may require reintervention).
Contraindications / Limitations
Invasive angiography risk â Diagnostic catheter angiography carries 0.5-1.0% risk of stroke/ TIA; non-invasive methods (CTA, MRA) are preferred for initial diagnosis. NASCET measurement on CTA or MRA is acceptable but may have different calibration.
ECST vs NASCET measurement discrepancy â The European Carotid Surgery Trial (ECST) method measures stenosis using the estimated original lumen diameter (including plaque), yielding higher stenosis percentages for the same lesion. Conversion: NASCET % = (ECST % - 40%) / 0.6 (approximate). Always specify which method was used.
Difficulty in measuring distal ICA diameter â If the distal ICA is diseased (post-stenotic dilation, tandem stenosis), measurement may be inaccurate. Use a normal segment beyond the stenosis (typically 2-4 cm distal to bifurcation).
Total occlusion (100% stenosis) â NASCET cannot differentiate near-occlusion with minimal residual lumen vs true occlusion; careful contrast injection and timing needed. CTA or MRA may be more accurate for occlusion.
Tandem lesions or intracranial stenosis â NASCET measures extracranial ICA only. Intracranial stenosis requires separate assessment (WASID method).
Dissection or fibromuscular dysplasia (FMD) â Non-atherosclerotic causes of stenosis (dissection, FMD, vasculitis) have different natural history and treatment; NASCET thresholds may not apply.
Calcified plaque on CTA â Heavy calcification may cause blooming artifact, overestimating stenosis on CTA; correlate with duplex ultrasound velocity criteria.
Poor distal ICA opacification â Low contrast injection rate, severe stenosis, or very slow flow may cause incomplete opacification, simulating occlusion. Use longer injection or catheter in proximal ICA if needed.
NASCET vs ECST vs CC vs Doppler Velocity
| Method | Formula / Criteria | Advantages | Disadvantages | Clinical Use |
|---|---|---|---|---|
| NASCET (North American) | Stenosis % = (1 - [Minimal residual lumen] / [Normal distal ICA]) Ă 100 | Validated in large RCTs (NASCET, CREST), standard for decision-making, reproducible | Requires normal distal ICA (may be diseased), invasive angiography or CTA needed | Gold standard for CEA/CAS decision-making; symptomatic and asymptomatic trials used NASCET |
| ECST (European) | Stenosis % = (1 - [Minimal residual lumen] / [Estimated original lumen]) Ă 100 | More physiologic (compares to original lumen), easier on angiography | Overestimates stenosis compared to NASCET (by 10-20%), not used in US trials | Historical; converted to NASCET for guideline application; rarely used today |
| CC (Common Carotid) | Stenosis % = (1 - [Minimal residual lumen] / [Normal distal CCA]) Ă 100 | Useful when distal ICA is diseased | Less validated, not used in major trials | Alternative if ICA not suitable (rare) |
| Doppler Ultrasound (Velocity Criteria) | Peak systolic velocity (PSV) ICA/CCA ratio, end-diastolic velocity (EDV) | Non-invasive, no radiation, widely available, can assess plaque morphology (echolucency, ulceration) | Operator-dependent, calcified plaque may obscure, cannot differentiate near-occlusion from occlusion | First-line screening; CEA/CAS decision based on velocity criteria (e.g., PSV >230 cm/s for 70% stenosis) or confirm with CTA/MRA |
| CTA (Computed Tomography Angiography) | Lumen diameter measurement similar to NASCET (but on axial or MPR images) | Non-invasive, 3D reconstruction, assesses plaque composition (calcified vs non-calcified), arch anatomy | Contrast nephropathy risk, radiation, calcium blooming artifact, overestimates stenosis with dense calcium | Pre-procedural planning for CEA/CAS; alternative to diagnostic angiography |
| MRA (Magnetic Resonance Angiography) | Time-of-flight (TOF) or contrast-enhanced MRA; lumen measurement | Non-invasive, no radiation, no contrast (if TOF), excellent for plaque characterization (IPH, LRNC) | Overestimates stenosis (flow-related signal loss), longer acquisition time, contraindications (pacemaker, claustrophobia) | Alternative to CTA; especially good for plaque morphology (intraplaque hemorrhage, thin/ruptured cap) |
Last Comprehensive Review: 2026